<DOC>
	<DOCNO>NCT02226380</DOCNO>
	<brief_summary>Purpose : This aim study evaluate efficacy safety neoadjuvant chemotherapy modify FOLFOX6 ( mFOLFOX6 ) regimen impact survival series local advance gastric cancer patient . Patients method : The study prospective non-randomized study . Patients histopathologically confirm locally advanced gastric cancer ( T2-T4 N+ ) enrol study . Patients give mFOLFOX6 scheme 3 cycles.A radical gastrectomy D2 lymphadenectomy schedule 3-6 week completion preoperative chemotherapy . Down-staging assess compare pretreatment clinical stag postoperative pathologic stag patient underwent radical surgery . Tumor down-staging grade pathologic response include statistical correlation tumor regression induce mFOLFOX6 neoadjuvant chemotherapy survival.The primary endpoint 3-year overall survival , secondary endpoint disease-free survival , R0 resection rate , toxicity prediction response .</brief_summary>
	<brief_title>FOLFOX6 Neoadjuvant Chemotherapy Local Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Eligibility criterion include histologically confirm gastric cancer , gastrooesophageal junction ( GEJ ) may involve , bulk tumour stomach ; age ≥18 year old , ECOG performance status score ≤2 , prior chemotherapy , TNM stage T2T4 positive regional lymph node endoscopic ultrasound compute tomography ( CT ) , adequate hematological , heart , liver renal function ( ALT AST≤2.5 UNL , total bilirubin ≤1.5 UNL , serum creatinine ≤1.5 UNL ) . Patients second malignancy evidence severe uncontrolled systemic disease exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>